English (UK)
中文版
Astrocyte Pharmaceuticals 
Astrocyte Pharmaceuticals is a preclinical CNS drug development company advancing breakthrough therapeutic agents for treating brain injury patients. Astrocyte is developing the proprietary small molecule pharmaceutical agent AST-004 for acute administration to patients who have suffered a stroke, TBI, or concussion. This product would be administered by intravenous injection by emergency responders or a medical professional within 24 hours of injury to limit neuronal damage and cell death. Our approach at Astrocyte Pharmaceuticals differs significantly from historical neuroprotective attempts as we focus on a non-neuronal cell type, the astrocyte, which is the most common cell type in the human brain and has only recently received broader attention as an important cellular target for therapeutic research. The company recently demonstrated AST-004's significant efficacy in an NHP stroke study that mirrors the planned Phase 2 clinical study, and large safety margins in GLP toxicology studies. The company completed its Series A financing in Q4 2020.
Dr. William Korinek
CEO
Aventurine Capital Management, LLC
We provide a human innovation ecosystem offering commercially focused support for inventors.
DEEP TECH FUNDING REINVENTED WITH SCIENCE, FOR SCIENCE
6 practice areas: AI, Robotics, Life Science, Quantum Computing, Energy, Secure Platforms & Networks
Mr. Avery Lu
Investment Research LeadBALINBAC THERAPEUTICS, INC.
Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.
Mr John Gregg
CEOBioPegasus, LLC
BioPegasus, LLC specializes in a cost-effective and robust post-proteomics and post-protein and peptide array technology biomarker and target discovery technology platform. This proprietary platform is unique and transformative, allowing systematic, thorough and unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time. It aims to accelerate novel therapeutic and diagnostic development for some devastating diseases to improve our health and quality of life. These diseases include autoimmune diseases, cancer, and, in particular, Alzheimer’s disease.
BioPegasus' technology platform provides a revolutionary tool for systematical and thorough studying novel molecular interactions and mechanism of actions with any molecule of interest. The platform can be used to provide contract services with royalty payment potential to research institutions and companies in IVD, biotech and pharma sectors. The technology can also be packaged into commercial product(s) with a user manual for sale in the market world-wide.
BioPegasus currently is operated by its founder looking for an investor(s), partner(s), and sponsor(s)/client(s) or any form of collaboration/interest.
Dr. Tianlin Ma
FounderBiostage, Inc.
The company’s novel Cellframe™ technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Our Cellframe technology is based on over 20 years of scientific progress in the fields of tissue engineering, cell biology and material science. Cellframe technology combines the best attributes of a synthetic scaffold with tissue engineering and cell biology to create what may be a revolutionary method of addressing organ damage.
Biostage has been developing its new generation of organ implants as a platform capable of being used in the esophagus and main airways (trachea and bronchi). The current platform, based on our Cellframe technology, represents a complete re-engineering of our earlier organ scaffold and cell technology to better stimulate the regenerative properties of each of these organs. Biostage’s Cellframe technology platform is used to create organ specific Cellspan implants. Recent large animal data showed promising results as our Cellframe technology applied to the esophagus achieved the regeneration of esophageal tissue.
Mr. Shunfu Hu
VP of Business Development and OperationsBioValleyCHINA Ventures
Assist Consultation, Assistance, Service
• Identify Distribution Opportunities, Partners, Joint Ventures
• Guidance for Product Registration (SFDA), Regulatory Issues
• Intellectual Property Assessment
• Develop Successful Business Strategy
• Marketing/Analysis
• Manufacturing/Sourcing
• Investment Advisory
Paul DeRidder
PresidentBioxytran/Pharmalectin
Academic study on a small number of patients with the first drug candidate had positive results. The viral load was reduced to zero in all mild/moderate patient after a few days. The drug is not toxic and had no adverse effects. It can prevent spread of infection in 24 hours. It is complementary to vaccination and can prevent infection from close contact. Next step is stage III trials for a bigger group of patients.
We are looking for investors to fund our next phase.
Responsive Web Design powered by 